Disclosure of onset-predictive biomarker results to research participants at risk of genetic frontotemporal dementia: a European perspective

Abstract Background As understanding of biomarkers for genetic frontotemporal dementia (FTD) advances, there is a need to develop onset-predictive biomarker tests (OPBTs) to detect changes before the onset of symptoms. OPBTs can be used to recruit carriers or individuals at 50% risk of carriership i...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Charlotte H. Graafland, Eline M. Bunnik, Barbara Borroni, Arabella Bouzigues, Sergi Borrego-Écija, Eino Solje, Caroline Graff, Jonathan D. Rohrer, John C. van Swieten, Laura Donker Kaat, Harro Seelaar
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2025-12-01
Цуврал:	Alzheimer’s Research & Therapy
Нөхцлүүд:	Clinical trials Disclosure Frontotemporal dementia Ethics Biomarkers
Онлайн хандалт:	https://doi.org/10.1186/s13195-025-01930-4
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!